Physiologically Based Pharmacokinetic (PBPK) Modeling of Everolimus (RAD001) in Rats Involving Non-Linear Tissue Uptake

Everolimus is a novel macrolide immunosuppressant developed for the prophylaxis of allogeneic renal or cardiac transplant rejection. Treatments with immunosuppressants are often associated with organ toxicity that is linked to high organ exposure. Therefore, gaining insight into the pharmacokinetics of everolimus in various organs is highly desirable especially those organs of therapeutic interest or those that pose safety concerns. The aim of this work was to characterize the disposition kinetics of everolimus in rats by physiologically based pharmacokinetic (PBPK) modeling.Blood and tissue samples were collected from male Wistar rats over 24 hr following intravenous (iv) bolus and iv infusion of 1 mg/kg and 10 mg/kg/2 hr of everolimus. Further blood samples were collected between 1 and 170 hr from a third group of rats, which received iv infusion of 1 mg/kg/2 hr of everolimus. Drug concentrations in blood and tissues were determined by a liquid chromatography reverse dilution method. Distribution of everolimus between blood fractions was determined in vitro at 37°C.The results of the study demonstrated that everolimus exhibited moderate non-linear binding to red blood cells. Also, the tissue-to-blood concentration ratio decreased in all tissues as blood concentration increased. A PBPK model involving non-linear tissue binding was able to successfully describe the observed data in blood and all the organs investigated. The highest binding potential was observed in thymus, lungs, and spleen with the greatest tissue affinity observed in thymus, skin, and muscle as compared to other tissues. Everolimus exhibited a high clearance rate that was limited to the hepatic blood flow (47.2 ml/min/kg). The PBPK model was also able to predict the venous blood concentration reasonably well following oral administration. The oral bioavailability value, as estimated with the PBPK, was 12% and was similar to the value obtained by non-compartmental analysis.In conclusion, A PBPK model has been developed that successfully predicts the time course of everolimus in blood and a variety of organs. This model takes into account the non- linear binding of everolimus to red blood cells and tissues. This model may be used to predict everolimus concentration–time course in organs from other species including humans.

[1]  M Rowland,et al.  Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  S. Urien,et al.  Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique , 1992, Investigational New Drugs.

[3]  T. Terasaki,et al.  Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. , 1983, Journal of pharmaceutical sciences.

[4]  W. Jusko,et al.  Species differences in sirolimus stability in humans, rabbits, and rats. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[5]  Malcolm Rowland,et al.  Physiologic modeling of cyclosporin kinetics in rat and man , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Ryosei Kawai,et al.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  U. Christians,et al.  Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. , 2001, Transplantation proceedings.

[8]  T. Terasaki,et al.  Physiologically Based Pharmacokinetic Model for β-Lactam Antibiotics I: Tissue Distribution and Elimanation Rates , 1983 .

[9]  B A Telfer,et al.  Tissue water content in rats measured by desiccation. , 1997, Journal of pharmacological and toxicological methods.

[10]  S. Sehgal.  Immunosuppressive Profile of Rapamycin , 1993, Annals of the New York Academy of Sciences.

[11]  R. Abraham,et al.  Immunopharmacology of rapamycin. , 1996, Annual review of immunology.

[12]  O. Cole,et al.  Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. , 1998, Transplantation proceedings.

[13]  K. Sewing,et al.  Structural elucidation by electrospray mass spectrometry: An approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD , 1998, Journal of the American Society for Mass Spectrometry.

[14]  Ryosei Kawai,et al.  Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[15]  W. Weimar,et al.  Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation. , 1999, Transplantation.

[16]  T. Waldmann,et al.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.

[17]  M. Lemaire,et al.  Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[18]  G. Berry,et al.  Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. , 2000, Transplantation.

[19]  Andrew Crowe,et al.  In Vitro and In Situ Absorption of SDZ-RAD Using a Human Intestinal Cell Line (Caco-2) and a Single Pass Perfusion Model in Rats: Comparison with Rapamycin , 1998, Pharmaceutical Research.

[20]  J. Ringers,et al.  Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. , 2000, Transplantation.